OnabotulinumtoxinA (BOTOX ®): A guide to its use in preventing headaches in adults with chronic migraine

CNS Drugs

Volumn 26, Issue 8, 2012, Pages 717-723

  Lyseng Williamson, Katherine A ^a   Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Clinical Q and A; Botulinum toxin A; Headache; Migraine

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; FLUNARIZINE; NEUROTOXIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; CLINICAL TRIAL (TOPIC); DISABILITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; HEADACHE; HUMAN; INJECTION SITE PAIN; LONG TERM CARE; LOW DRUG DOSE; MIGRAINE WITH AURA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NECK MUSCLE; NECK PAIN; NOCICEPTION; PHASE 3 CLINICAL TRIAL (TOPIC); PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SYMPTOM; TRANSFORMED MIGRAINE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

BOTULINUM TOXINS, TYPE A; CHRONIC DISEASE; HEADACHE; HUMANS; INJECTIONS, INTRAMUSCULAR; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84863696685     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11208930-000000000-00000     Document Type: Review

References (26)

1. D'Andrea G, Colavito D, Dalle Carbonare M, et al. Migraine with aura: conventional and non-conventional treatments. Neurol Sci 2011 May; 32 Suppl. 1: S121-9
2. Lipton RB. Chronic migraine, classification, differential diagnosis, and epidemiology. Headache 2011; 51 Suppl. 2: 77-83
3. Oleson J, Bousser M-G, Diener H-C, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-6
4. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine: revised report of an EFNS task force. Eur J Neurol 2009; 16: 968-81
5. Antonachi F, Dumitrache C, De Cillis I, et al. A review of European treatment guidelines for migraine. J Headache Pain 2010 Feb; 11 (1): 13-9
6. Tfelt-Hansen P, Olesen J. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 2012; 26 (5): 375-82
7. BOTOX 50, 100 or 200 units: UK summary of product characteristics. Marlow, UK: Allergan Ltd., 2011 Dec
8. BOTOX (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use: US prescribing information. Irvine (CA): Allergan, Inc., 2011 Nov
9. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005 Oct; 26 (5): 785-93
10. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011 Nov; 17 Suppl. 1: S28-33
11. Pavone F, Luvisetto S. Botulinum neurotoxin for pain management: insights from animal models. Toxins (Basel) 2010 Dec; 2 (12): 2890-913
12. Yiangou Y, Anand U, Otto WR, et al. Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons. J Pain Res 2011; 4: 347-55
13. Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011 Nov-Dec; 51 (10): 1573-7
14. Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30 (7): 793-803
15. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30 (7): 804-14
16. Dodick DW, Turkel CC, Degryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50 (6): 921-36
17. Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011; 51: 1358-73
18. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008; 28: 484-95
19. Therapeutic Goods Administration. Australian public assessment report for botulinum toxin type A [online]. Available from URL: http://www.tga.gov.au/pdf/ auspar/auspar-botox.pdf [Accessed 2011 Dec 2]
20. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011 Oct 11; 77 (15): 1465-72
21. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012; 26 (2): e1-e9
22. Naumann M, Carruthers A, Carruthers J, et al. Metaanalysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX) across multiple indications. Mov Disord 2010 Oct 15; 25 (13): 2211-8
23. Olesen J, Tfelt-Hansen P. Licence for Botox in so-called chronic migraine. Lancet 2010; 376 (9755): 1825-6
24. Cady RK, Schreiber CP, Porter JAH, et al. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 2011; 51 (1): 21-32
25. Mathew NT, Jaffri SFA. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (Topamax) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009; 49 (10): 1466-78
26. Frampton JE. Onabotulinumtoxin A (BOTOX): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs 2012; 72 (6): 825-45